Pharmalink: Gaining momentum
In order to prepare for the start of Phase III trials with its lead drug candidate Nefecon, Pharmalink AB has made several new appointments. Among them Kari Sandvold, who will take over as Vice President Pharmaceutical Development and Manufacturing.
Sandvold, who holds a MSc in Pharmaceuticals, joined Pharmalink in May 2016. Her most recent position was as Head of Pharmaceutical Development at Orexo AB. Before joining Orexo in 2003, she held several positions at Pfizer.
Apart from Sandvold, Pharmalink has also appointed Nora Sjödin as Vice President Regulatory Affairs, Ann-Kristin Myde as Project Director and Liselotte Theorell as Quality Assurance and Drug Safety Director
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium